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Introduction 
The amphotropic murine leukemia virus (A-MuLV) has the ability to infect a variety of 
mammalian cell lines. This broad tropism together with its relatively simple 
organization has made this retrovirus a particularly promising vector for gene therapy. 
Although A-MuLV-derived vectors are now broadly used for gene therapy purposes 
(Batra et al. 1998; Cardinali et a.l 1998; Yang et al. 1999), little is known about the 
biology of their receptor. Cell surface receptors for AMuLV have been cloned (filler 
et al. 1994; van Zeijl et al. 1994; Wilson et a.l 1995) and demonstrated to serve as 
sodium-dependent phosphate (Na+/Pi) transporters in the normal physiology of diverse 
cell types (Kavanaugh et al. 1994, Wilson et al. 1995). Based on their structural and 
functional characteristics, these molecules, together with the gibbon ape leukemia virus 
(GALV) receptor, were classified as type III Na+/Pj transporters (Kavanaugh and Kabat 
1996) and were designated Pit-2 and Pit-1, respectively (Eiden et al. 1996, Kavanaugh 
et al. 1994). 
The activity and protein levels of the Pit-2 phosphate transporter/viral receptor are 
highly regulated in cells. Pit-2-mediated NaVPi uptake can be specifically blocked by 
infection of cells with A-MuLV (Wilson et al. 1995), and expression of amphotropic 
envelope protein (Env) in murine cells also has been shown to inhibit phosphate 
transport ÇCavanaugh et al. 1994). A similar loss of the Pit-1 transporter functions has 
been described for GALV-infected cells (Olah et al. 1994). Phosphate concentration 
changes also have been shown to regulate Pj uptake activity. Depletion of extracellular 
phosphate was found to increase Pit-2 and Pit-1 expression three- to fivefold in 
fibroblasts {Kavanaugh et al. 1994). Moreover, removal of phosphate from the culture 
media was shown to both increase the amount of Pit-2 mRNA and the quantity of a 71-
kDa protein specifically recognized by antibodies against Pit-2. This increase in Pit-2 
mRNA levels observed in response to Pi depletion appeared to be regulated not at a 
transcriptional but rather at a posttranscriptional level due to enhanced mRNA stability 
{Chien et al. 1998). In a study carried out with CHO cells, the levels of Pit-2 at the cell 
surface remained unchanged following variations of the phosphate supply, but the 
efficiency of phosphate uptake and retrovirus entry was found to be inversely related to 
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the extracellular phosphate concentration {Rodrigues et al. 1999). These results 
suggested that Pit-2 activities may be modulated by posttranslational modifications of 
the cell surface Pit-2 proteins in response to changes in phosphate concentration and 
that such modifications are required to activate phosphate transporter and retrovirus 
receptor functions. 
Protein kinases, including members of the protein kinase C family, regulate numerous 
biological functions, including intracellular protein trafficking and the activities of 
different ion transporters {Nishizuka et al. 1995). Previously, it was shown that sodium-
dependent phosphate (Na/P¡)' transport was stimulated by protein kinase C (PKC) and 
inhibited by protein kinase A in NIH 3T3 cells. Phorbol 12-myristate 13-acetate (PMA), 
an activator of PKC, was found to cause a rapid (within 10 min) stimulation of short 
term Na/P¡ uptake <Qlah et al. 1993). However, at that time the identity of the Na/P¡ 
transporter stimulated in response to PMA was not known, and this prevented further 
characterization of the PKC-mediated activation of the transporter. More recently, cell 
surface receptors for the gibbon ape leukemia virus (Glvr-1 and Pit-1) and the 
amphotropic murine leukemia virus (Ram-1, Ear, and Pit-2) were demonstrated to serve 
as Na/Pj transporters in the normal cellular physiology of diverse cell types QCavanaugh 
et al. 1994; Olah et al. 1994; Wilson et al. 1995). We have established in the presented 
studies that PMA treatment of cells enhances Na+/P¡ uptake via stimulation of Pit-2 and 
that this effect is specifically mediated through PMA activation of the PKCe isoform. 
Cells infected by retroviruses display a strong resistance to superinfection by viruses 
that utilize the same receptor as the pre-infecting virus but retain susceptibility to 
viruses that use a different receptor. This phenomenon, termed superinfection 
interference, is thought to arise from interaction of the viral envelope protein with the 
receptor Coffin 1996). However, the level and site of this interaction remain obscure. 
While superinfection and receptor down-regulation phenomena are widely recognized, 
and methods based on viral superinfection interference are commonly used in murine 
retrovirus research {Eglitis et al. 1993; Miller and Wolgamot 1997), the mechanisms 
underlying the loss of transporter and receptor functions are largely unknown {Coffin 
1996). To determine the fate of Pit-2 in A-MuLV-producing infected and control 
uninfected cells, we constructed plasmids capable of efficiently expressing £-epitope-
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and green fluorescent protein (GFP)-tagged human Pit-2 proteins in mammalian cells. 
The results presented in this thesis demonstrate that the tagged Pit-2 receptors are 
localized to the plasma membrane in uninfected NIH 3T3 cells. However, when NIH 
3T3 cells expressing these tagged proteins are infected with A-MuLV, the tagged 
receptors are no longer detectable in the plasma membrane but are found redistributed 
to punctate structures within the cytosolic compartment. This loss of Pit-2 viral 
receptors from the cell membrane apparently is responsible for superinfection 
interference induced with A-MuLV infection. 
Amino acid sequence data obtained for the Pit-1 and Pit-2 receptor-transporters has 
revealed multiple sites potentially susceptible to phosphoiylation by protein kinases, 
including PKC, which are found within the hydrophilic cytoplasmic domain of both 
transporters between residues 250 and 450. Indeed, parathyroid hormone-induced 
regulation of transporter function mediated through activation of protein kinase A and 
PKC has been described for type I and II Na/Pj transporters present in kidney brush-
border membranes (Chien et al. 1996). In addition to parathyroid hormone, 
prostaglandin E2, insulin-like growth factor 1, and vitamin D3 all have been reported to 
regulate Na/Pj uptake through activation of PKC in osteoblasts, another cell type that 
uses high levels of inorganic phosphate {Coffin 1996; Eglitis et al 1993; Eiden et al. 
1996). It also has been suggested that a phospholipase C^-PKC signaling pathway is 
responsible for the up-regulated Pj transport observed with platelet-derived growth 
factor treatment of osteoblast-like cells. (Kavanaugh and Kabat 1996; Kavanaugh et al. 
1994; Kim and Cunningham 1993). In osteoblasts it is possible that the more 
ubiquitously expressed type III Na/Pi transporters, such as Pit-1 and Pit-2, might be 
involved in the PKC-regulated uptake of Pj. Conversely, activation of PKC has been 
reported to inhibit Pj uptake in opossum kidney cells, which may indicate different 
regulation of the renal type I and II transporters (fhien et al. 1998; Lehel et al 1995; 
Marsh and Helenius 1989). These differences in PKC-mediated regulation of P uptake 
may be a consequence of different expression patterns of either PKC and/or Na/Pj 
transporter isotypes in different cell lines. 
One of the major difficulties in determining which PKC isotypes are involved in 
regulating Na/Pj transport is that different cell types express various combinations of 
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PKC isoforms. Protein kinase C is a family of at least 11 serine- and threonine-specifie 
phosphotransferase isoenzymes that are characterized by a high degree of homology in 
their catalytic and cysteine-rich domains. Although the possible role(s) of different PKC 
isozymes in cell growth and differentiation has been well studied (for review, see 
Nishizuka and Nakamura 1995), much less is known of their potential involvement in 
modulating intracellular trafficking of transmembrane receptors and up-regulation of ion 
transporters. In this study we have sought to determine which type of Na/Pj 
transporter/viral receptor is regulated by PMA activation of PKC and which PKC 
isotype(s) may be involved in the up-regulation of Na/Pj uptake in NIH 3T3 cells. The 
results presented in this thesis indicate that the Pit-2 Na/P; transporter/viral receptor is 
specifically activated by PMA stimulation of PKC2. 
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Materials and Methods 
Materials— Dulbecco's modified Eagle's medium (DMEM) and fetal calf serum were 
purchased from Biofluids Inc. (Rockville, MD). PMA, bisindolylmaleimide, and Gö 
6976 were products of Calbiochem (San Diego, CA). 32P-Labeled monopotassium 
phosphate was from ICN (Costa Mesa, CA). The PKC isotype-specific antisense and 
scrambled oligonucleotides (ISIS 17260, PKCc antisense; ISIS 17261, PKC2 scrambled 
control) were from ISIS Pharmaceuticals. PKC2 isotype-specific polyclonal antibodies 
were purchased from Life Technologies, Inc.; PKC^-specific monoclonal antibodies 
were from Upstate Biotechnology (Lake Placid, NY); and PKC&- and PKC?-specific 
monoclonal antibodies were from Transduction Laboratories (Lexington, KY). 
The pEGFP-N 1 enhanced GFP (EGFP) tagging vector is available from Clontech (Palo 
Alto, Calif.), and the Xpress protein expression system (pTrcHis) and plasmids coding 
for endoplasmic reticulum (ER)- and mitochondrion-targeted GFP were obtained from 
Invitrogen (San Diego, Calif.). The early endosomal protein (EEA1) fragment (amino 
acids 1252 to 1411)-EGFP chimera was a gift from Tamás Balla (National Institute of 
Child Health and Human Development, National Institutes of Health, Bethesda, Md.). 
The p£MTH expression vector was developed in our laboratory as described previously 
(Olah et ál. 1994). LysoTracker DND-99, Texas red-conjugated transferrin, Alexa 
488 phalloidin, and dextran 10 were purchased from Molecular Probes, Inc. (Eugene, 
Oregon, USA). 
Primary antibodies. PKCe isotype-specific polyclonal antibodies (Gibco BRL, 
Gaithersburg, Maryland, USA) were used to detect epitope-tagged Pit-2 proteins. 
Anti-GFP polyclonal antibody was purchased from Chemicon International Inc. 
(Temecula, California, USA). The Pit-2-specific rabbit antiserum was produced in our 
laboratory using a recombinant HaPit-2 (the hamster homolog of Pit-2) cytoplasmic 
loop fragment (amino acids 272 to 462) as antigen (Wilson et al. 1995). The bacterial 
recombinant vector, pTrcHisA-EARcA21, expressing this fragment was overexpressed 
in Escherichia coli and then affinity purified using a His-Ni2+ column (Novagen, 
Madison, Wisconsin, USA). One and one-half milligrams of the approximately 95% 
pure cytosolic loop fragment protein was used as antigen for immunization of two 
rabbits. A-MuLV pig antiserum (lot no. 77S000445) and purified goat anti-Rausch 
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leukemia virus gp69/71 antibodies (lot no. 80S000018) were obtained from the 
NCI/BCB Reagents Repository (Camden, New Jersey, USA). 
Secondary antibodies. Cy3-conjugated anti-rabbit and anti-mouse immunoglobulin 
(IgG), fluorescein-conjugated anti-pig IgG, and Texas red-conjugated anti-goat IgG 
secondary antibodies were purchased from Jackson ImmunoResearch Laboratories, Inc. 
(West Grove, Pennsylvania, USA). Peroxidase-labeled goat anti-rabbit and anti-mouse 
IgGs were from Kirkegaard & Perry Laboratories, Inc. (Gaithersburg, Maryland, USA.). 
DNA constructs, (i) Primers. The PCR primers used were as follows: 
1, GAGGTCGACATGGCCATGGATGAGTATTTGTGG; 
2, TCCTACTTTGGTGAAGACCTGATGCCCACAGGCAAATTACAAAAAGAAGGT 
GC; 3, GTCTTCACCAAAGTAGG^GAAGCCTTTTATTTTCCTCCGCATCCACGG; 
4. GTATACGCGTCACATATGGAAGGATCCCATACATG: 
5, GAAGCCCCGGGCCACATATGGAAGGATCCCATACATG. Recognition sites for 
restriction endonucleases used for cloning are underlined; overlapping sequences are 
italicized. 
(ii) pTrcHisA-EARcA21. The Sacl-BamHl restriction fragment of hamster Pit-2 (EAR, 
HaPit-2) was ligated into the pTrcHisA bacterial expression vector cut with Sacl-BgKl. 
(iii) pPit2e-eMTH. Insertion of the ^-epitope tag into the cytoplasmic loop of Pit-2 was 
accomplished in two steps by overlapping PCR using primer pairs 1-2 and 3-4 in the 
first rounds of PCRs. The products of these reactions then were purified, annealed, and 
used as template for a final PCR using primers 1 and 4. The purified product was cut 
with Sall-Mlul and ligated into the p£MTH vector cut with Xhol-Mlul. A second t-
epitope tag was added at the C-terminal end of this cytosolic loop-tagged Pit-2E, with 
insertion and expression of this construct in the p£MTH vector. 
(iv) pPit2-EGFPNl. Construction of human Pi-2 C-terminally tagged with GFP was 
accomplished using primers 1 and 5 to amplify human Pit-2 cDNA. The PCR-amplified 
product was cut with restriction endonucleases SaA-Xmal and then ligated into the 
pEGFP-Nl vector. 
Generation of overexpressor cell lines. — The construction of expression vectors and 
establishment of PKC overproducer cell lines were carried out as described previously 
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(Lehel et al. 1995). The PKCa, -E, and -S plasmid constructs were prepared in the 
pEMTH vector, and overexpressor cell lines were established following protocols 
described elsewhere {Lehel et al 1994). NIH 3T3 cells were transfected with either the 
control expression vector p£MTH or pPit2£;-£MTH, expressing the e-epitope-tagged Pit-
2, using electroporation. Stably transfected cell lines were selected with G418 
(0.8 mg/ml). Individually picked colonies (10 from each transfection) were selected and 
pooled for further studies to minimize potential artifacts attributable to anomalies 
associated with special clones. The mixed populations of stable Pit-2££ overexpressor 
cells were used only through 12 to 14 passages in culture to negate possible outgrowth 
of one particular population of cells. NIH 3T3 and CHO-K1 cells also were transiently 
transfected by electroporation with either the control vector pEGFP-Nl or the pPit2-
EGFPN1 expression vector. Cells transiently expressing Pit-2-GFP were used for 
further studies 24 h after transfection. 
Cell Culture— Retrovirus-infected and vector-transduced NIH 3T3 cells were cultured 
in DMEM supplemented with 10% fetal calf serum. After the cells reached confluency, 
the medium was changed to serum-free DMEM for 24 h. To induce overexpression of 
any ectopic gene products, the cells were incubated in the presence or absence of 20 pM 
zinc acetate, as indicated, to induce the up-regulation of the metallothionein promoter of 
the pEMTH vector (Olah et al. 1994). 
Phosphate Uptake Measurement— Sodium-dependent phosphate uptake was 
determined as described previously (Olah et al 1993). 
Retrovirus Infections— NIH 3T3 murine fibroblasts and mink lung fibroblasts (ATCC 
CCL 64) were maintained in DMEM supplemented with 10% (v/v) fetal bovine serum. 
NIH 3T3 cells were infected with wild type amphotropic murine retrovirus (A-MuLV) 
strain 4070A or the 57A Friend strain of ecotropic MuLV (E-MuLV). Mink fibroblasts 
expressing gibbon ape leukemia retrovirus (GALV)- competent PiT-1 were infected with 
wild type A-MuLV strain 4070A or infected with a GALV strain (SEATO), as 
described previously {Olah et al. 1994). Productive infection was monitored by 
measuring the reverse transcriptase activity found in the cell media of the infected cells 
{Wilson andEiden 1991). 
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Cells productively infected with A-MuLV were demonstrated to be resistant to 
challenge infection with A-MuLV envelope vectors but not with E-MuLV envelope 
vectors. Cells productively infected with E-MuLV were resistant to E-MuLV envelope 
vectors but retained susceptibility to A-MuLV infectivity. 
Antisense Oligonucleotide Treatment— NIH 3T3 fibroblasts were cultured in 150-mm 
tissue culture dishes until they reached -80% confluency. The cells then were harvested 
by hypsinization, washed with DMEM, and resuspended in 400 pi of cytosalt 
electroporation buffer (75% cytosalts (120mM KCI, 0.15 mM CaCl2, 10 mM K2HPO4, 
pH 7.6, 6.5 mM MgCfc) and 25% Opti-MEM I). Twenty-pi aliquots of PKC isotype-
specific or scrambled control oligonucleotides were added to the cells resuspended in 
prechilled BTX disposable electroporation cuvettes (P/N 640; 4-mra gap) to reach the 
indicated concentrations and then incubated on ice for 5 min. The oligonucleotides 
indicated were introduced into the cells by electroporation with a BTX Electro Square 
Porator (settings: low voltage mode, 99 msec; charge voltage, 475 V; pulse length, 
1 msec; number of pulses, 4). The electroporated cells were kept at room temperature 
for 10 min and then seeded onto 100-mm tissue culture plates for immunoblot studies 
and onto 24-well plates for Pj uptake measurements. Western blot analysis of PKC 
isotypes and Pi uptake studies were carried out 24 h after introduction of the antisense 
oligonucleotides. 
Western blot analysis. For protein extraction, cells were washed with ice-cold 
phosphate-buffered saline (PBS), harvested by scraping into lysis buffer (20 mM Tris-
HC1 [pH 7.4], 5 mM EGTA, 1 mM phenylmethylsulfonyl fluoride, 20 mM leupeptin), 
and disrupted in a Dounce homogenizer. Cell homogenates were fractionated by 
differential centrifiigation into nuclear (pellet of 800 x g centrifugation for 10 min), 
particulate (plasma membrane-enriched; 16,000 x g, 1-h pellet of the nucleus-free 
800 x g supernatant), and cytosolic (16,000 x g supernatant) fractions. Proteins of each 
fraction were separated by precast sodium dodecyl sulfate-4 to 20% polyacrylamide gel 
(Owl Separation Systems, Portsmouth, N.H.) electrophoresis and electrophoretically 
transferred from the gel onto Protran membranes (Schleicher & Schuell, Keene, N.H.); 
immunoreactive proteins were detected as described elsewhere (Olah et al. 1994). 
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Laser scanning confocal microscopy. NIH 3T3 cells were grown on glass 
multichamber slides. Vector control cells and cells overexpressing Pit-2££ (human Pit-2 
protein double tagged with the e epitope) were fixed in 4% buffered formaldehyde 
solution (Sigma) for 30 min at 4°C and then blocked with PBS containing 1% bovine 
serum albumin (BSA) and 0.6% Triton X-100 for l h at room temperature. 
Immunostaining was carried out with the indicated primary antibodies in the same PBS 
solution for 2 to 3 h at room temperature. After three 5-min washes in PBS, the 
appropriate secondary antibodies were applied for 1 h at room temperature and washed 
with PBS. The slides then were mounted with Vectashield antifade reagent (Vector 
Laboratories, Burlingame, California) and covered with glass coverslips. Cells 
transiently overexpressing Pit-2-EGFP were labeled with cell organelle markers and 
mounted without fixation. For the LysoTracker, dextran 10, and transferrin receptor 
localization experiments, NIH 3T3 fibroblasts transiently transfected with pPit2-
EGFPN1 by electroporation were plated on glass chamber slides and labeled with the 
markers 24 h posttransfection. Lysosomes were labeled with LysoTracker Red DND-99 
according to the manufacturer's suggestions. To visualize the recycling endosome pool, 
cells were washed three times with serum-free DMEM and then incubated in the same 
medium containing 20 pg of Texas red-conjugated transferrin per ml for 30 min. The 
cells then were washed, chased with unlabeled transferrin (20 pg/ml) for 30 min, and 
mounted for fluorescence microscopy as described above. For labeling the late 
endosomal compartment, cells were incubated with 1 mg of Texas red-labeled dextran 
10 per ml for 45 min, rinsed with medium, and incubated in fresh medium for 60 min to 
wash out the dextran prior to imaging. Confocal fluorescent images were collected with 
a Bio-Rad MRC 1024 confocal scan head mounted on a Nikon Optiphot microscope 
with a 40x or 60x planapochromat lens. A krypton-argon gas laser provided excitation 
at 488 and 568 nm. Emission filters of 598/40 and 522/32 were used for collecting red 
and green fluorescence, respectively, in channels 1 and 2, while phase-contrast images 
of the same cell were collected in the third channel using a transmitted light detector. 
After sequential excitation, red and green fluorescent images of the same cell were 
merged for colocalization of GFP with cellular organelle markers. 
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Results and Discussion 
Most retroviruses have been found to use distinct cell surface receptors for specific 
cellular recognition and infection. Furthermore, studies have revealed that the normal 
cellular function of a number of these viral receptors is to serve as membrane transport 
proteins (Weiss and Tailor 1995). NIH 3T3 cells have been found to express several of 
these viral receptor/transporters, including Pit-1, Pit-2, and the cationic amino acid 
transporter CAT/y+, as determined by viral infection studies and reverse transcription-
polymerase chain reaction analysis. NIH 3T3 cells are susceptible to infection by A-
MuLV via Pit-2 and to infection with EMuLV via the CAT/y+ amino acid transporter. 
However, because of the presence of specific point mutations in the endogenous murine 
Pit-1, Pit-1 is not functional as a GALV receptor in NIH 3T3 cells. 
Effect of Viral Infection on PMA-induced Activation of Phosphate Transport-
Previous studies have established that infection of cells with retroviruses that selectively 
recognize either Pit-1 or Pit-2 resulted in the specific down-modulation of phosphate 
uptake mediated by that receptor/transporter (Kavanaugh et al. 1994; Wilson et al. 
1995). A similar phenomenon has been observed to occur with the E-MuLV CAT/y+ 
receptor (Wang et al. 1991; 1992). To examine which of the viral receptor/Pi 
transporters are subject to regulation by PMA activation of PKC, studies were carried 
out with NIH 3T3 cells infected with different Gtype retroviruses. The results presented 
in Fig. 1A demonstrate that infection with A-MuLV decreased short term (2-min) basal 
Na/Pj transport (from 900 ± 9 1 to 404±28pmol of Pj/min/mg of protein) and, 
importantly, completely abolished the activation of Pi transport noted with exposure of 
cells to PMA. Infection of cells with EMuLV would not be expected to alter P, uptake, 
because this vims binds to a distinct cell surface cationic amino acid transporter (Wang 
et al. 1991; 1992). Thus, to control for possible pleiotropic effects of retrovirus 
infection on Na/Pi transport, P uptake experiments were carried out with NIH 3T3 cells 
infected with E-MuLV (Fig. IB). The results indicated that infection with E-MuLV did 
not alter either basal or PMA-induced Na/Pj transport. 
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As noted, GALV binds to the Pit-1 receptor of mink fibroblasts and selectively down-
modulates Pi uptake caused by Pit-1 (Olah et al. 1994). To determine whether Na/Pi 
transport mediated by Pit-1 or Pit-2 is stimulated by activation of PKC, I, uptake was 
measured in mink cells infected with either A-MuLV or GALV. Infection of these cells 
with A-MuLV again completely abolished the activation of Pj transport noted with 
exposure of cells to PMA (Fig. 1C). Although GALV infection did result in an ~25% 
decrease in basal Na/Pi transport, which apparently is attributable to down-modulation 
of Pit-1, it did not decrease the PMA-induced stimulation of Pj uptake noted in these 
cells (Fig. ID). Taken together, these results obtained with C-type retrovirus-infected 
cells indicate that Pit-2 is the Pj transporter/viral receptor that is up-regulated with 
exposure of cells to PMA. 
Effect of Selective PKC Inhibitors on PMA-induced Up-regulation of Pit-2 Pj 
Transport— Although studies have established a general role for PKC in the regulation 
of several membrane transport mechanisms, little is known concerning the functional 
role(s) of specific PKC isotypes in these regulatory processes. Thus, studies were 
initiated to determine which PKC isotype(s) are involved in mediating the PMA-
induced up-regulation of the Pit-2 transporter/receptor in NIH 3T3 cells. NIH 3T3 cells 
express a limited, but representative, set of different PKC isozymes (PKC01, PKCS, 
PKC2, and PKC?) (Lehel et al. 1994; Mischak et al. 1993). Because PMA does not 
directly activate atypical PKC?, this isotype would not appear to be involved in the short 
term PMA-induced activation of Pit-2 Pj transport. Thus, experiments were initiated to 
address which class of PKC isoform stimulates P transport in response to activation by 
PMA. Two different PKC inhibitors were used to determine whether the PMA-induced 
activation of Na/Pj transport in NIH 3T3 cells was mediated via a conventional, Ca2+-
dependent (PKC00), or a novel, Ca2+-independent (PKC§ and PKC2), isotype. Addition 
of the pan-specific bisindolylmaleimide inhibitor, which inhibits both classical and 
novel isotypes, resulted in pronounced inhibition of the PMA-induced activation of 
Na/Pj uptake (Fig. 2). Conversely, treatment of the cells with the Go 6976 PKC 
inhibitor, which selectively inhibits only the classical PKC isotypes, did not cause 
significant inhibition of the PMA-induced up-regulation of Pj transport. These results 
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suggested that the classical P K C isoform likely was not involved in mediating the 
activation of Na/Pj uptake by Pit-2 with exposure of NIH 3T3 cells to PMA. 
Effect of Overexpression of PKC Isotypes on Na/Pj Uptake— To further resolve 
which of the PKC isotype(s) may be involved in mediating the PMA activation of the 
Na/Pj uptake, we used NIH 3T3 cells overexpressing PKC0, -e, or -? isozymes to 
determine the ability of each isotype to enhance Pit-2 P, transport activity in the absence 
of PMA treatment. The cell cultures were shifted to serum-free media and incubated in 
the presence of 20 pM zinc acetate for 24 h to enhance expression of the indicated PKC 
isotype directed by the metallothionein promoter of the p2-MTH vector. Overexpression 
of PKC2 was found to increase Na/Pj uptake, whereas overexpression of P K C , P K C , 
and PKC? did not appreciably alter the level of Pj transport relative to' the level 
determined in vector control cells (Fig. 3A). Exposure of the P K C overexpressor cells 
to 1 pM PMA resulted in only an additional 15-20% increase in Pj transport. Western 
blot analysis showed that the level of expression was similar for each of the E epitope-
tagged PKC isotypes (Fig. 3B). These results indicate that the selective overexpression 
of PKC2 alone can mimic the stimulation of Na/Pj uptake observed with PMA treatment 
of wild type cells. 
Effect of PKC-specific Antisense Oligonucleotide on PMA-induced Stimulation of 
Pit-2 Pj Transport— To further support the findings that P K C is the isotype involved 
in mediating the PMA-induced activation of the Pit-2 Pj transporter, studies were carried 
out with PKC-selective antisense oligonucleotide (AON) to specifically inhibit PKC-2 
in the cell. As shown in Fig. 4A, pretreatment of NIH 3T3 cells with increasing 
concentrations of PKC-AON significantly decreased the expressed levels of PKC and 
had no effect on the levels of P K C , P K C , or PKC?. Densitometric scanning to 
quantitate the intensity of the PKC2 bands of cells treated with PKC-AON relative to 
AON scrambled controls indicated relative band densities of 1.0,0.59, and 0.28 with 
0.24, 1.2, and 2.4 mM oligonucleotide treatment, respectively. Importantly, treatment of 
the cells with PKC-AON did result in inhibition of PMA-induced up-reguMon of Pj 
transport (Fig. 4B). Treatment of cells with scrambled oligonucleotides did not have any 
effect on either the intracellular level of P K C or PMA activation of Na/Pj uptake. 
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Similar experiments with PKC&-AON (ISIS 17254) caused a significant decrease in the 
levels of PKC& but had no effect on PMA-induced stimulation of Pi uptake (data not 
shown). These data provide additional evidence to support the exclusive involvement of 
PKCe in mediating PMA activation of Pit-2. 
The suggestion that different PKC isotypes play distinct functional roles in the cell by 
phosphorylating either isoform- or subcellular compartment-specific substrates is 
widely accepted. However, few studies have been reported that establish that a specific 
PKC isotype may selectively regulate a given biological function. Although a role for 
PKC has been implicated in the regulation of numerous membrane transport 
mechanisms (Veldman et al. 1998; Ribeiro et al. 1996; Corey et al 1994; Enyedi et al. 
1996; Rokaw et al 1996), little information is available on the specific PKC isotype(s) 
involved in the regulation of these transport activities. Karim et al. attributed the 
modulation of the Na/H antiport to both PKC a and PKCe. PKCe also has been 
implicated in the stimulation of anionic amino acid transport (Franchi-Gazzola et al. 
1996), and treatment with antisense oligonucleotides to PKC§ has been shown to block 
the Kl-adrenergic activation of Na-K-2C1 cotransport (Liedtke and Cole 1997). The 
evidence reported here indicates that PKC5 is involved in mediating the PMA-induced 
up-regulation ofNa/P, uptake by the Pit-2 transporter/viral receptor. 
The Pit-1 and Pit-2 viral receptor/Pj transporters share 56% amino acid identity {van 
Zeijl et al. 1994). Hydropathy analysis of Pit-1 and Pit-2 suggested the presence of at 
least two clusters of putative transmembrane-spanning sequences, along with a large 
intracellular hydrophilic domain located between the sixth and seventh transmembrane 
helices (Olah et al 1994; Wilson and Eiden 1991). There are a number of consensus 
phosphorylation sites in both Pit-1 and Pit-2, particularly within the hydrophilic loop 
domain. Thus, it is likely that PKC? may directly phosphorylate Pit-2 to stimulate Na/P, 
uptake. 
However, another mechanism of regulation found with other transporters is induced 
redistribution of the transporter from intracellular stores to the plasma membrane. For 
example, insulin has been reported to regulate the intracellular trafficking of glucose 
transporter 4 (Hudson et al. 1992). Previously, we have shown that PKC? can regulate 
16 
Golgi-related functions, including protein trafficking and secretion (Lehel et al. 1995). 
To address this possibility, studies were carried out to determine whether PMA still was 
able to enhance Pj uptake under conditions in which vesicle trafficking from the Golgi 
to the plasma membrane was blocked by incubating cells at room temperature and by 
treatment of cells with nocodazole (to disrupt microtubules) and cytochalasin D (to 
disrupt actin filaments). It was found that these treatments did not block PMA-induced 
activation of P; uptake.2 Although these results indicate that PKC5 does not act by 
modulating the trafficking of PiT-2 from the Golgi to the plasma membrane, they do not 
fully mle out the possibility that PKC? might act to mediate the rapid recruitment 
(fusion) of an existing pool of Pit-2-containing vesicles to the plasma membrane. 
In addition to their role as representative members of an important family of phosphate 
transporters, Pit-1 and Pit-2 are of particular interest as the cell surface ieceptors for the 
GALV and A-MuLV retroviruses, respectively. Many current gene therapy protocols 
use GALV- or A-MuLV-enveloped vectors (Barquinero et al 1995; Kavanaugh and 
Kabat 1996). A basic knowledge of murine leukemia virus receptor regulation and 
trafficking is likely to be useful in the development and improvement of gene therapy 
protocols based on the use of these retroviral vectors. Although our results clearly 
indicate that PKCe is involved in regulating Na/Pj uptake by Pit-2, it remains to be 
determined whether PKC5-mediated regulation of the Pit-2 transporter/viral receptor 
might influence recognition of the viral envelope protein and viral entry into the cell. 
e-Epitope-tagged human Pit-2 overexpressed in NIH 3T3 fibroblasts and GFP-
tagged human Pit-2 overexpressed in CHO-K1 cells retain their functional and 
regulatory properties. PCR products of Pit-2 were produced and then cloned into 
either the psMTH or pEGFP-Nl vector as described in Materials and Methods. The 
resulting Pit2e-eMTH construct (Fig. 5A) was used to transfect NIH 3T3 cells, and cell 
lines stably overexpressing Pit-2ss were selected. Overexpression of Pit-2ee in NIH 
3T3 fibroblasts resulted in only a slight increase in Pj uptake. However, following Zn2+ 
induction of the metallothionein promoter to enhance expression of the Pit-2ee protein, 
Pi uptake was significantly increased (160%) compared to vector control. Moreover, e-
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epitope-tagged Pit-2 transporters retained the ability to be up-regulated by PMA, as 
demonstrated by a proportional increase in Pj uptake detected with the tagged Pit-2 
transporters following PMA treatment of the overexpressor cells (Fig. 5C). A-MuLV 
infection of the Pit-2ee overexpressor cells resulted in a significant (60%) decrease in Pj 
uptake activity, indicating that the Pj transporter activity of the tagged Pit-2 molecules 
was blocked by A-MuLV infection in a manner similar to that observed with the native 
or wild-type Pit-2 transporters (Fig. 5D). CHO-K1 cells normally are resistant to A-
MuLV infection due to the presence of inhibitors secreted by CHO-K1 cells that can 
inhibit endogenous HaPit-2 receptor function. This resistance can be overcome by 
expressing the human form of the Pit-2 transporters/receptors in CHO-K1 cells. To test 
the Pit-2-EGFP chimera (Fig. 5B) for A-MuLV receptor function, we transiently 
transfected plasmid pPit2-EGFP into CHO-K1 cells and then infected the transiently 
transfected cells with A-MuLV vectors carrying a B-galactosidase reporter gene as 
described elsewhere ((Chaudry et al. 1999). CHO-K1 cells transfected with pPit2-EGFP 
were found to be sensitive to A-MuLV, as indicated by the formation of blue foci in 
response to expression of the B-galactosidase reporter gene. No blue foci were detected 
in CHO-K1 cells transfected with the control pEGFP-Nl and A-MuLV vectors (data not 
shown). As expected, since CHO-K1 cells are resistant to AMuLV infection, the virus 
titer obtained for A-MuLV vectors on CHO-K1 control was 0 infectious unit/ml. The 
titer obtained with CHO-K1 cells expressing Pit-2 was 2,000 infectious units/ml, which 
compared to a value of 1,800 infectious units/ml with CHO-K1 cells expressing 
epitope-tagged Pit-2. Further, expression of the Pit-2-EGFP chimera significantly 
increased Pj uptake compared to vector control, and PMA treatment enhanced Pit-2— 
EGFP-mediated Pj transport (data not shown). These results indicate that the e-epitope-
tagged Pit-2 and the Pit-2-EGFP chimera both retain A-MuLV receptor function and 
that both Pit-2ee and Pit-2-EGFP retain all of the functional and regulatoiy 
characteristics of wild-type Pit-2 phosphate transporter activity. 
Western blot analysis of overexpressed e-epitope- and GFP-tagged human Pit-2 
phosphate transporter/retrovirus receptor proteins in NIH 3T3 cell lysates. 
Immunostaining of protein blots of a plasma membrane enriched particulate fraction 
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prepared from Pit-2ee overexpressor cells with anti-e antibody revealed an 
immunoreactive 70-kDa band (Fig. 6A, lane 2). Interestingly, the e-epitope-tagged Pit-2 
protein detected in the 16,000 x g particulate fraction prepared from AMuLV-infected 
cells was found to migrate as a lower-molecular-mass protein of about 60 kDa (Fig. 6A, 
lane 3). The change in Pit-2 receptor migration rate was specific for AMuLV-infected 
cells. Pit-2 detected in the particulate fraction prepared from cells infected with 
ecotropic Moloney MuLV (which binds to the cationic amino acid transporter, M-
CAT1), migrated at a molecular weight similar to that observed with the uninfected 
control cells (Fig. 6A, lane 4). No immunoreactive Pit-2ee band was detected in the 
protein sample prepared from the vector control cell line (Fig. 6A, lane 1). Endogenous 
PKCe was detected with the anti-PKCe antibody as a 90-kDa band and served as an 
internal control of the amount of protein loaded per lane. Western blot analysis using 
anti-HaPit-2 rabbit antiserum in place of the e-tag antibody resulted in a similar pattern 
(Fig. 6B). Again, Pit-2 was found to migrate as a lower-molecular-weight band in A-
MuLV-infected NIH 3T3 cells compared to uninfected and ecotropic Moloney MuLV-
infected cells. These results indicate that infection of NIH 3T3 cells expressing epitope-
tagged Pit-2 with A-MuLV (which utilizes Pit-2 as its cell surface receptor) correlates 
with the presence of a more rapidly migrating form of Pit-2 and results in the loss of P 
transporter function. One explanation for this observation is that the Pit-2 present in A 
MuLV-infected cells is more susceptible to a peptidase, which may catalyze the 
proteolytic processing of Pit-2. A second possibility is that the band shift noted with Pit-
2 concomitant with A-MuLV superinfection may be due to the blockage of required 
posttranslational modifications such as phosphorylation and/or glycosylation which may 
take place before or at the time of Pit-2 trafficking to the plasma membrane. In a related 
study using Moloney MuLV-infected NIH 3T3 cells, the MCAT-1 ecotropic virus 
receptor was observed to also migrate as a lower-molecular-weight protein. This 
increase in electrophoretic mobility noted with MCAT-1 from infected cells was found 
to be due to a blockage of normal N-linked glycosylation. It was proposed that binding 
of newly synthesized ecotropic vims envelope surface protein, gp70, with the MCAT-1 
receptor in the ER acted to prevent normal glycosylation of MCAT-1 (Kim and 
Cunningham 1993). 
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Subcellular redistribution of Pit-2ee in NIH 3T3 cells productively infected with 
A-MuLV. Fluorescence laser confocal microscopy was used to provide optical 
sectioning of cells. Basically, the image obtained with confocal laser microscopy is 
equivalent to a thin section across the entire length or width of the cell and does not 
represent the cell as a whole. The results obtained revealed that Pit-2ss localized mainly 
to the plasma membrane when overexpressed in control NIH 3T3 cells (Fig. 7A, 1 and 
2; Fig. 7B, 2 control). In addition, faint staining also was detected at a perinuclear 
location in some of those uninfected cells. This may represent a Golgi-localized pool of 
newly synthesized Pit-2ee. Likewise, Pit-2-GFP transiently coexpressed in the Pit-2ee 
overexpressor cells also exhibited plasma membrane localization (Fig. 7B, 1 control). 
Importantly, the epitope-tagged Pit-2 was not detected at the plasma membrane 
following productive infection of the overexpressor cells with A-MuLV; rather, it was 
found predominantly redistributed to an unidentified intracellular location (Fig. 7A, 3; 
Fig. 7B, 2 A-MuLV). Some staining was detected at an apparent nuclear membrane 
location in A-MuLV-infected cells. A similar pattern of Pit-2-GFP redistribution was 
observed when A-MuLV producer Pit-2ee overexpressor cells were transiently 
transfected with the pPit2-EGFPNl construct (Fig. 7B, 1 A-MuLV). Merging of Fig. 3B 
pictures 1 and 2 resulted in areas of yellow signal indicating colocalization of Pit-2ee 
and Pit-2-GFP (Fig. 7B, 3). In both infected and uninfected NIH 3T3 fibroblasts, the e-
epitope-tagged Pit-2 transporters colocalized with the Pit-2-GFP chimeras, indicating 
that the presence of the bulky GFP protein at the C terminus did not affect the 
localization of Pit-2-GFP (Fig. 7B, 3). The epitope-tagged Pit-2 transporters remained 
localized to the plasma membrane in ecotropic Moloney MuLV (Fig. 7A, 4)- and 57A 
Friend MuLV (not shown)-producing cells, indicating that the observed redistribution 
of Pit-2 was A-MuLV specific and not attributable to general effects associated with 
retroviral infection. 
Colocalization of AMuLV envelope protein with the overexpressed epitope-tagged 
Pit2 transporter/receptor in productively infected Pit-2 overexpressor NIH 3T3 
cells. To define the relationship between infection of cells with A-MuLV and the 
redistribution of Pit-2 receptor within the virus producer fibroblasts, double 
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immunostaining experiments were performed with fluorescent labeling and confocal 
microscopy using A-MuLV-specific pig antiserum and antibodies against the e-epitope 
tag of Pit-2ee as described in Materials and Methods. Anti-e-epitope staining for Pit-
2ee in the A-MuLV-infected cells using Cy3-conjugated secondary antibodies resulted 
in the characteristic punctate intracellular (internalized) pattern noted previously for Pit-
2ee in productively infected cells (Fig. 7C, Pit-2ee). The distribution of A-MuLV 
within the infected NIH 3T3 cells was visualized by fluorescein-conjugated goat anti-
pig IgG secondary antibodies. Uninfected cells were stained in the same way to set the 
background signal to zero. A-MuLV particles also appeared as disperse punctate 
structures throughout the cytoplasm, with denser distribution occurring in areas similar 
to the patterns represented by Pit-2ee (Fig. 3C, A-MuLV). Merging of the pictures 
resulted in areas of yellow signal indicating colocalization of Pit-2 and A-MuLV in 
punctate structures throughout the cytosol (Fig. 7C, merged). Alternatively, A-MuLV-
infected NIH 3T3 cells were transiently transfected with the pPit2-EGFPNl construct 
and stained for A-MuLV gp70 envelope protein with goat anti-Rausch murine leukemia 
vims gp69/71 antibody using Texas red-conjugated anti-goat IgG secondary antibodies. 
This goat anti-Rausch murine leukemia vims gp69/71 antibody has been shown to 
recognize the proline-rich region of MuLV protein, including the A-MuLV gp70 
envelope protein QVeimin Wu et al. 1998). The distribution of Pit-2-GFP and AMuLV 
gp70 protein was visualized under laser scanning confocal microscopy as described in 
Materials and Methods. Again, Pit-2-GFP showed subcellular localization similar to A-
MuLV gp70, and merging the pictures resulted in yellow areas indicating colocalization 
of Pit-2-GFP and A-MuLV gp70 envelope protein (Fig. 7D). 
Pit-2se overexpressed in A-MuLV producer fibroblasts did not colocalize with 
commonly used markers for intracellular organelles. The pattern of subcellular 
redistribution of Pit-2es in A-MuLV-infected cells was similar in some respect to that 
reported for the human immunodeficiency virus type 1-induced redistribution of CD4 
molecules to the ER (Bour et al. 1995). Therefore, we used ER-targeted GFP to 
determine a possible colocalization with Pit-2ee in A-MuLV-infected fibroblasts. 
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Double-channel fluorescent laser confocal imaging of Pit-2ee-overexpressing A-MuLV 
producer cells showed no colocalization of Pit-2se with the ER marker GFP (Fig. 8C). 
Furthermore, no colocalization of Pit-2ee was observed either with GFP alone (which 
exhibits both cytoplasmic and nuclear staining) (Fig. 8A) or with a PKCs zinc finger 
fragment 3-GFP chimera (which localizes predominantly to the Golgi complex (Lehel 
et al. 1995) (Fig. 8B). To test the possibility that a modified Pit-2 may be redistributed 
to the lysosomes rather than transported to the plasma membrane, we assessed the 
subcellular localization of Pit-2-GFP chimeras in live cells stained with the lysosome 
marker LysoTracker as described in Materials and Methods. Again, no colocalization of 
Pit-2-GFP with the lysosome marker was observed in the AMuLV-infected cells (Fig. 
8G). Experiments using Texas red-conjugated transferrin (a marker for recycling 
endosomes) or dextran 10 (a marker for late endosomes) together with Pit-2-GFP 
showed no colocalization with Pit-2-GFP in A-MuLV-infected five fibroblasts (Fig. 8E 
and F). Moreover, the subcellular localization of the epitope-tagged Pit-2ss pool was 
found to be different from that for mitochondria (with mitochondrion-targeted GFP as a 
marker) (data not shown) and from that for early endosomes with EEA1-GFP chimeras 
as a marker (Fig. 8D). 
Recently, it was reported that Pit-2 formed a physical association with actin Rodrigues 
and Heard 1999). Further, the formation of actin stress fibers was implicated in 
determining the cell- surface distribution of Pit-2, the internalization of the receptor in 
response to virus binding, and the capacity to process retrovirus entry. To determine 
whether the reported association between Pit-2 and actin was conserved after AMuLV 
infection, A-MuLV producer Pit-2ee-overexpressing cells were double stained with e-
tag antibody to detect Pit-2ee- and fluorescein-conjugated phalloidin to detect actin 
stress fibers. We were unable to detect colocalization of Pit-2ee and the actin network 
within A-MuLV producer fibroblasts (Fig. 8H). In addition, no apparent loss of actin 
cytoskeletal integrity was detected under those conditions, which might result from the 
loss of actin stress fibers or aggregation of actin near the cell surface as ¿scribed for 
other oncoretroviral transformation (Burridge 1985). 
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Cells infected with one retrovirus are typically resistant to superinfection with the same 
virus or other viruses that utilize the same receptor. This phenomenon of superinfection 
interference often involves the down-modulation of a specific cell surface viral receptor. 
For several retroviruses, interference involves depletion of receptors from the surface of 
infected cells. However, other mechanisms for superinfection interference have been 
proposed. For example, E-MuLV has been reported to bind to a conformationally 
mobile site on the mouse MCAT-1 receptor (Wang et al 1992). Binding of the envelope 
glycoprotein gp70 to the MCAT-1 viral recepWbasic amino acid transporter appears to 
slow down a conformational transition of the empty transporter required to move the 
viral binding site from the inside back to the outside of the cell. This results in a 
significant decrease in further viral infection mediated through this receptor. Yet the 
infected cells retain basic amino acid transport activity, which is required for cell 
viability. It has been suggested that interference in response to human 
immunodeficiency virus type 1 infection is more complex than with simpler 
retroviruses such as A-MuLV. In addition to env, at least two other genes also have 
been reported to contribute to this process. The product of vpu interacts with newly 
synthesized CD4 and causes its degradation if it is associated with the envelope protein, 
while nef expression causes loss of the CD4 receptor from the cell surface (flour et al. 
1995). Infection by cytopathic retroviruses such as certain strains of feline leukemia 
vims is not associated with superinfection interference. It has been suggested that this 
delay or failure to establish superinfection interference may be responsible for the cell 
killing noted with infection by such cytopathic viruses (Temin 1986). However, 
infection with other subgroups of FeLV does lead to superinfection interference. This 
FeLV subgroup-specific superinfection interference does not appear to be due to a 
blockade or down-regulation of other cell components required for vims entry (¡leinhart 
et al. 1993). 
Infection of cells with A-MuLV does induce resistance to superinfection, and it has 
been proposed that this interference may in part involve down-modulation of the Pit-2 
receptor (Kavanaugh and Kabat 1996). Previously, it was established that Pit-2-
mediated Na+/Pj uptake can be specifically blocked by infection of cells with A-MuLV 
(Wilson et al 1995), and expression of the amphotropic envelope protein in murine cells 
also was shown to inhibit phosphate transport mediated by Pit-2 (Kavanaugh et al 
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1994). However, the mechanism responsible for the loss of Pit-2 transporter and viral 
receptor functions with A-MuLV infection has not yet been elucidated. Here we have 
presented experimental findings obtained with epitope-tagged forms of human Pit-2 
designed to determine the fate of Pit-2 in A-MuLV-infected cells. Results are presented 
to show that the tagged Pit-2 receptors are localized to the plasma membrane in 
uninfected NIH 3T3 cells. However, when cells expressing the tagged Pit-2 were 
productively infected with A-MuLV, the tagged protein was no longer present at the 
plasma membrane. Rather, tagged Pit-2 now was found distributed to punctate 
structures within the cytosolic compartment, where it was found to colocalize with the 
A-MuLV gp70 envelope protein. The intracellular pool of epitope-tagged Pit-2 
phosphate transporter/viral receptor present in A-MuLV-infected cells was shown to be 
a more rapidly migrating, apparently lower-molecular-weight form of Pit-2. A-MuLV, 
but not E-MuLV, appears to infect cells by releasing nucleocapsid into the cytoplasm 
following direct fusion at the plasma membrane and not through an endocytic pathway 
as a complex with Pit-2 receptor (Warsh and Helenius 1989). Thus, the loss of Pit-2 
from the plasma membrane in A-MuLV-infected cells does not appear to be due to a 
virus-induced endocytic process. Rather, it is conceivable that in A-MuLV-infected 
cells, complexes of newly synthesized Pit-2 receptor and the A-MuLV envelope 
glycoprotein may form shortly after protein synthesis. The newly synthesized Pit-2 
found in these complexes may not be available for required covalent modifications or 
may be more susceptible to proteolytic modification. In turn, the posttranslational 
modifications blocked with the formation of intracellular Pit-2-A-MuLV envelope 
protein complexes may be required for normal Pit-2 processing and trafficking to the 
plasma membrane. The absence of Pit-2 receptors from the plasma membrane appears 
to be responsible for the superinfection interference observed in cells productively 
infected with A-MuLV. 
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Summary 
The membrane receptors for the gibbon ape leukemia retrovirus and the amphotropic 
murine retrovirus serve normal cellular functions as sodium-dependent phosphate 
transporters (Pit-1 and Pit-2, respectively). Earlier studies established that activation of 
protein kinase C (PKC) by treatment of cells with phorbol 12-myristate 13-acetate 
(PMA) enhanced sodium-dependent phosphate (Na/Pi) uptake. Studies now have been 
carried out to determine which type of Na/Pi transporter (Pit-1 or Pit-2) is regulated by 
PKC and which PKC isotypes are involved in the up-regulation of Na/Pi uptake by the 
Na/Pi transporter/viral receptor. It was found that the activation of short term (2-min) 
Na/Pi uptake by PMA is abolished when cells are infected with amphotropic murine 
retrovirus (binds Pit-2 receptor) but not with gibbon ape leukemia retrovirus (binds Pit-
1 receptor), indicating that Pit-2 is the form of Na/Pi transporter/viral receptor regulated 
by PKC. The PKC-mediated activation of Pit-2 was blocked by pretreating cells with 
the pan-PKC inhibitor bisindolylmaleimide but not with the conventional PKC isotype 
inhibitor Go 6976, suggesting that a novel PKC isotype is required to regulate Pit-2. 
Overexpression of PKCepsilon, but not of PKCalpha, -delta, or -zeta, was found to 
mimic the activation of Na/Pi uptake. To further establish that PKCepsilon is involved 
in the regulation of Pit-2, cells were treated with PKCepsilon-selective antisense 
oligonucleotides. Treatment with PKCepsilon antisense oligonucleotides decreased the 
PMA-induced activation of Na/Pi uptake. These results indicate that PMA-induced 
stimulation of Na/Pi uptake by Pit-2 is specifically mediated through activation of 
PKCepsilon. 
Amphotropic murine leukemia virus (A-MuLV) utilizes the Pit-2 sodium-dependent 
phosphate transporter as a cell surface receptor to infect mammalian cells. Previous 
studies established that infection of cells with A-MuLV resulted in the specific down-
modulation of phosphate uptake mediated by Pit-2 and in resistance to superinfection 
with A-MuLV. To study the mechanisms underlying these phenomena, we constructed 
plasmids capable of efficiently expressing epsilon epitope- and green fluorescent 
protein (GFP)-tagged human Pit-2 proteins in mammalian cells. Overexpression of 
epsilon-epitope-tagged Pit-2 transporters in NIH 3T3 cells resulted in a marked increase 
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in sodium-dependent P(i) uptake. This increase in P(i) uptake was specifically blocked 
by A-MuLV infection but not by infection with ecotropic MuLV (E-MuLV) (which 
utilizes a cationic amino acid transporter, not Pit-2, as a cell surface receptor). These 
data, together with the finding that the tagged Pit-2 transporters retained their A-MuLV 
receptor function, indicate that the insertion of epitope tags does not affect either 
retrovirus receptor or P(i) transporter function. The overexpressed epitope-tagged 
transporters were detected in cell lysates, by Western blot analysis using both epsilon-
epitope- and GFP-specific antibodies as well as with Pit-2 antiserum. Both the epitope-
and GFP-tagged transporters showed almost exclusive plasma membrane localization 
when expressed in NIH 3T3 cells, as determined by laser scanning confocal 
microscopy. Importantly, when NIH 3T3 cells expressing these proteins were 
productively infected with A-MuLV, the tagged transporters and receptors were no 
longer detected in the plasma membrane but rather were localized to a punctate 
structure within the cytosolic compartment distinct from Golgi, endoplasmic reticulum, 
endosomes, lysosomes, and mitochondria. The intracellular Pit-2 pool colocalized with 
the virus in A-MuLV-infected cells. A similar redistribution of the tagged Pit-2 proteins 
was not observed following infection with E-MuLV, indicating that the redistribution of 
Pit-2 is not directly attributable to general effects associated with retroviral infection but 
rather is a specific consequence of A-MuLV-Pit-2 interactions. 
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Figure 1. Effects of infection of cells with the amphotropic murine leukenia virus, 
the ecotropic murine leukemia virus, and the gibbon ape leukemia virus on the 
activation of sodiumdependent R uptake by PMA. NIH 3T3 cells were productively 
infected with wild type A-MuLV (4, and EMuLV (B, °) and then treated with 1 pM 
PMA fir the periods indicated. Mink fibroblasts were infected with wild type AMuLV 
(C, °) and wild type GALV-1 (D, °) and then treated with 1 pM PMA for the times 
indicated. Uninfected cells were used as control for each experiment ( • ) . Pj transport 
activity was determined as described under "Experimental Procedures." The data are 
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Figure 2. Effect of PKC inhibitors on the PMA-induced stimulation of P, uptake. 
Serum-starved NIH 3T3 cells were preincubated with 0.01% dimethylsulfoxide as 
solvent control (O), 500 nM bisindolylmaleimide (•), or 500 nM Go 6976 (=) for 4 h, 
and then treated with 1 pM PMA for the times indicated. Pi transport activity was 
determined as described under "Experimental Procedures." Data represent the 
mean±S.E. of three independent experiments performed in duplicate (n = 6). As 
determined by Student's t test, the inhibitory effects noted with bisindolylmaleimide 
were statistically significant (p < 0.05), whereas the slight effects noted with Go 
6976 (p > 0.4) were not significant. 
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Figure 3. Effect of a 
overexpression of different PKC 
isotypes on Pj uptake. A, vector 
control and PKC isotype 
overexpressor NIH 3T3 cells were 
serum starved for 24 h in the 
presence (+) or absence (~~) of 
20 pM zinc acetate. Short temi (2-
rnin) sodium-dependent Pj 
transport activity was determined B 
in control and overexpressor cells 
as described under "Experimental 
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Procedures." Each column represents the mean ± S.E. of three independent 
experiments performed in duplicate. B, Western blot analysis of the levels of 
c epitope-tagged PKC isotypes in total cell extracts of the indicated PKC isotype 
overexpressor. NIH 3T3 cells were serum starved for 24 h in the presence of 
20 pM zinc acetate, and total cell extracts then were prepared. Electrophoresis of 
total 20-pg protein lysate was carried out on 4-20% SDS-polyacrylamide gels, 
and immunoblot analysis was carried out with anti-e epitope tag antibody as 
described under "Experimental Procedures." 
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Fig. 4. Effect of PKC^-specific 
antisense oligonucleotide treatment of 
NIH 3T3 cells on PMA-induced 
stimulation of Na/Pj-uptake. The 
antisense (a) and scrambled control (c) 
oligonucleotides at the concentrations 
indicated were introduced into NIH 3T3 
cells by electroporation, and the 
electroporated cells then were incubated 
for 24 h in the presence of the 
introduced oligonucleotides. A, selective 
decrease in PKCc protein levels with 
treatment of cells with PKC5-specific 
antisense oligonucleotides. Cells treated 
with the indicated concentrations of 
PKCe-specific antisense (a, ISIS 17260) _ _ _ _ _ _ „ 
Q. d C d v a C 
or scrambled control (f, ISIS 17261) oligonucleotides for 24 h were harvested by 
scraping into lysis buffer. Aliquots of the cell lysates containing 100 pg of total 
protein were analyzed for changes in the levels of specific PKC isoforms by 
Western blotting using PKCe, a , 6 and C izotype-specific antibodies. Western 
blot data represent a characteristic expression pattern of three similar 
experiments. B, treatment of NIH 3T3 cells with PKCe-specific antisense 
oligonucleotides inhibited the PMA-induced increase in Pj uptake. Cells treated 
with the indicated concentrations of oligonucleotides for 24 h were exposed to 
0.01% dimethylsulfoxide (solvent control) or 1 pM PMA for 10 min, and short 
term ft transport activity then was determined as described. Data are presented as 
the fold increase in Pi uptake in response to PMA treatment above basal values 
determined in the presence of dimethylsulfoxide. Results are given as the 
average ± S.E. of three separate uptake experiments performed in duplicate. 
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Figure 5. Functional and regulatory properties of recombinant human Pit-
2 proteins Pit-2££ (A) and Pit-2-GFP (B). Short-term (2-min) Pi transport was 
determined in control p£MTH and pPit2£-£MTH-transfected NIH 3T3 fibroblasts 
as indicated in Materials and Methods. Cells were grown in serum-free medium 
with 20 pM zinc acetate to up-regulate the metallothionein promoter and then 
treated with 1 pM PMA for 10 min as indicated (C). (D) Pj uptake of p' MTH 
vector- and pPit2£-£MTH 
\ Pit-2re 
vector-transfected > • • H B M a M H K ) ¿'J-
fibroblasts, as well as in jj Pii2-OFP 
N 
these transfected cells 
G J c 
HBFFLH 
ptilalivi* finitsiimnbraiw <i"JH.iiü 
productively infected 
with A-MuLV. Each 
colunm represents the 
mean ± standard error of 
the mean of three 
independent experiments 
performed in duplicate. 
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Figure 6. Western blot analysis of cell lysates prepared from £-epitope -
tagged Pit-2 overexpressor fibroblasts productively infected with A-MuLV 
and E-MuLV. A 16,000 x g plasma membrane-enriched particulate fraction was 
prepared as described in Materials and Methods from control vector-transfected 
and Pit-2££ overexpressor fibroblasts, either uninfected or infected with AMuLV 
or E-MuLV, as indicated. £-Tag antibodies (1:2,000) (A) and rabbit Pit-2 
antiserum (1:500) (B) were used to detect Pit-2 in the particulate fraction of 
stable overexpressor cell vector Pit-2e£ 
lines. Closed arrows 
indicate Pit-2-specific g5 k i ) a . 
bands in uninfected and 
E-MuLV-infected cells; 
open arrows indicate Pit-2 
specific bands in A-
MuLV- infected cells. 
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Figure 7. Immunocytochemical localization of ^-epitope-tagged Pit-2 transporter 
in uninfected (A, land 2), and AMuLV-infected (A, 3), and E-MuLV-infected (A, 
4) overexpressor NIH 3T3 cells. e-Tag antibodies (1:1,000 dilution) and Cy3-labeled 
anti-rabbit IgG (1:1,000 dilution) were used as primary and secondary antibodies, 
respectively, to stain for overexpressed Pit-2££ transporters. Views 1 and 2 in panel B 
depict dual imaging of control and A-MuLV-infected cells cooverexpressing both Pit-2-
GFP chimeras and Pit-2££, respectively. The coexpressed e-epitope-tagged Pit-2 and the 
GFP-tagged Pit-2 were detected using fluorescent labeling and confocal laser 
microscopy as described in Materials and Methods. Panel C represents dual 
immunostaining of A-MuLV producer Pit - 2££- o verexpressing NIH 3T3 fibroblasts with 
-tag antibodies and with A-MuLV pig antiserum. Cells were prepared and fixed on 
glass microscope slides as described in Materials and Methods. Pit-2££ staining with t-
tag antibodies was carried out as described in the legend to Fig. 6. The same cells were 
also stained for A-MuLV, using l:500-diluted pig antiserum and 1:1,000-diluted 
fluorescein-conjugated anti-pig IgG secondary antibodies. Similarly stained uninfected 
and untransfected control NIH 3T3 cells were prepared to establish background levels 
for both the red and the green signals. Panel D shows AMuLV-infected NIH 3T3 cells 
transiently transfected for 24 h with the pPit2-EGFPNl construct and then stained for 
A-MuLV gp70 envelope protein with l:500-diluted goat anti-Rausch murine leukemia 
vims gp69/71 antibody and l:500-diluted Texas red-conjugated anti-goat IgG 
secondary antibodies. The distribution of Pit-2-GFP and A-MuLV gp70 protein was 
visualized under laser scanning confocal microscopy as described in Materials and 

























Figure 8. Dual immunostaining of overexpressed Pit-2 transporters with intracellular 
compartment markers in A-MuLV producer NIH 3T3 fibroblasts. A-MuLV producer, E-epitope-
tagged Pit-2 overexpressor cells were transiently transfected with pEGFP-Nl (A), pPKCe3-EGFPC3 
(Golgi-localizing chimera) (B), pER-GFP (coding for ER-targeted GFP) (C), and pEEAl-GFP (early 
endosome marker) (D), fixed, and stained with anti e-tag antibody as described in Materials and 
Methods. Alternatively A-MuLV-infected fibroblasts were transiently transfected with the pPit2-EGFP 
construct by electroporation and then labeled with transferrin (for recycling; endosomes) (E), dextran 
10 (for late endosomes) (F), and LysoTracker (for lysosomes) (G) as detailed in Materials and 
Methods. A-MuLV producer, E-epitope-tagged Pit-2££ overexpressor cells were fixed and double 
stained with e-epitope antibody and fluorescein-conjugated phalloidin (for actin staining) (H). Control 
untransfected NIH 3T3 cells were prepared in the same manner to establish background levels for the 
£-tag antibody signal. Top panels within each experimental set represent Pit-2; middle panels represent 
different intracellular compartment markers within the same cells; lower panels show the results 
obtained with merging of the red and green signals. 
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